ADORA3 and hepatocellular carcinoma: While our study did not specifically focus on the differential effects of ADORA3 activation in normal vs cancerous liver cells, it is worth noting that clinical trials of Namodenoson in HCC patients26,28 or in metabolic dysfunction-associated steatotic liver disease and MASH27 have reported no hepatotoxicity.